EmendoBio: Anocca signs licensing deal for EmendoBio's gene-editing tech
Anocca has entered a licensing agreement with EmendoBio for the use of the latter's OMNI-A4 nuclease, a gene editing technology.
Read full article »
Emendo is a biotechnology company that develops and commercializes gene-editing therapeutics for the treatment of genetic diseases.
Read more